Skip to main content
. Author manuscript; available in PMC: 2020 May 27.
Published in final edited form as: Curr Opin Oncol. 2008 Nov;20(6):639–649. doi: 10.1097/CCO.0b013e3283127095

Table 3.

Active histone deacetylase inhibitors clinical trialsa

HDACi Combination drug(s) Indication
Vorinostat Azacitidine, bortezomib, decitabine, docetaxel, 5-FU, doxorubicine, idarubicin, erlotinib, isotretinoin, gemcitabine, temozolomide, sorafenib, tamoxifen, flavopiridol, paclitaxel/bevacizumab, paclitaxel/carboplatin, gemcitabine/cisplatin or carboplatin, 5-FU/leucovorin calcium/oxaliplatin, isotretinoin/carboplatin, cytarabine/etoposide, irinotecan/5-FU/leucovorin, rituximab/ifosfamide/carboplatin/etoposide, radical prostatectomy, palliative radiotherapy CTCL, GBM, RCC, MDS, AML, ALL, CML, breast cancer, NSCLC, melanoma, lymphoma, advanced malignant pleural mesothelioma, advanced solid tumors, gliomas, nasopharyngeal cancer or nasal natural killer T-cell lymphoma, multiple myeloma, NHL, leukemia, colorectal cancer, GI cancer, prostate cancer, pelvic malignancy
Romidepsin Decitabine, flavopiridol, gemcitabine, bortezomib CTCL, PTCL, squamous cell carcinoma of the head and neck, NHL, refractory thyroid cancer, pulmonary and pleural malignancies, pancreatic, advanced solid tumors, relapsed myeloma, advanced lung, esophageal or pleural cancer
Belinostat Azacitidine, bortezomib, isotretinoin, carboplatin/paclitaxel Hepatocellular carcinoma, primary peritoneal cancer, fallopian tube cancer, B-cell NHL, T-cell lymphomas, MDS, thymic carcinoma, advanced hematological cancers, advanced solid tumors, lymphomas, ovarian cancer
LBH589 Ketoconazole, bortezomib, trastuzumab, dextromethorphan, gemcitabine, lenalidomide/dexamethasone, capecitabine/lapatinib, paclitaxel/carboplatin/bevacizumab CTCL, CML, MDS, NSCLC, advanced hematological malignancies, clear cell renal carcinoma, advanced solid tumors, multiple myeloma, breast cancer, malignant pleural mesothelioma
SB939 None Advanced or metastatic solid tumors
ITF2357 None Relapsed/refractory Hodgkin’s lymphoma
PCI-24781 (CRA-024781) None Advanced cancer
SNDX-275 Azacitidine, erlotinib, sargramostim (GM-CSF), exemestane NSCLC, AML, CML, MDS, breast cancer
MGCD0103 Azacitidine, docetaxel, gemicitabine AML, MDS, CLL, lymphoma, solid tumors, Hodgkin’s lymphoma, NHL
VPA Decitabine, bevacizumab, doxorubicin, etoposide, epirubicin, sunitinib, sorafenib, dasatinib, erlotinib, lapatinib, lenalidomide, karenitecin, azacitidine/carboplatin, azacitidine/ATRA, ATRA/theophyllamine, FEC 100 (5-FU, epirubicin, and cyclophosphamide), temozolomide/radiation therapy CLL, AML, MDS, GBM, small lymphocytic lymphoma, advanced thyroid cancer, nasopharyngeal carcinoma, ovarian cancer, NHL, advanced solid tumors, melanoma, advanced breast cancer, malignant mesothelioma, neuronal tumors and brain metastases

ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukemia; ATRA, all-trans retinoic acid; CML, chronic myelogenous leukemia; CTCL, cutaneous T-cell lymphoma; EOC, epithelial ovarian cancer; 5-FU, 5-fluorouracil; GBM, glioblastoma multiforme; GI, gastrointestinal; HDACi, histone deacetylase inhibitors; MDS, myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; NSCLC, nonsmall cell lung cancer; PTCL, peripheral T-cell lymphoma; RCC, renal cell carcinoma; VPA, valproic acid.

a

Further information regarding these clinical trials can be found at (http://www.cancer.gov/search/SearchClinicalTrialsAdvanced.aspx).